Literature DB >> 24274674

Prevalence of dyslipidaemia in patients with renal cell carcinoma: a case-control study in China.

Gui-Ming Zhang1, Yao Zhu, Lei Luo, Hai-Liang Zhang, Cheng-Yuan Gu, Li-Jiang Sun, Ding-Wei Ye.   

Abstract

OBJECTIVE: To examine the prevalence of dyslipidaemia in patients with renal cell carcinoma (RCC) in a Chinese population. PATIENTS AND METHODS: In all, 550 histologically confirmed RCC cases and 570 controls, matched for age and sex were included. Total cholesterol, triglyceride, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were assessed before treatment using standard techniques. The lipid profiles were defined as 'normal', 'borderline high', 'high' and 'low' according to Chinese Guidelines on Adult Dyslipidaemia. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression in both unadjusted and adjusted models.
RESULTS: Abnormal LDL elevation was common in RCC cases compared with controls (P < 0.001). Results for total cholesterol, triglyceride and HDL levels between groups were insignificant. The OR for RCC for high levels of LDL (≥160 mg/dL) compared with those with a normal LDL profile was 4.675 (95% CI 1.900-11.500). After adjustment for age, gender, body mass index, smoking status, hypertension, diabetes, total cholesterol and triglyceride, the coexistence of high levels of LDL and RCC was large and statistically significant (OR 8.955, 95% CI 3.371-23.786). There was a significant coexistence of RCC for participants with high LDL levels when subgroups of cases with clear cell subtypes and advanced T stages were compared with controls.
CONCLUSION: Abnormal LDL elevation was prevalent in Chinese patients with RCC. The results remain to be evaluated in prospective cohorts.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  dyslipidaemia; epidemiology; low-density lipoprotein; renal cell carcinoma

Mesh:

Year:  2014        PMID: 24274674     DOI: 10.1111/bju.12581

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Kidney cancer in Saudi Arabia. A 25-year analysis of epidemiology and risk factors in a tertiary center.

Authors:  Sultan S Alkhateeb; Ali S Alothman; Abdulmalik M Addar; Raed A Alqahtani; Tarek M Mansi; Emad M Masuadi
Journal:  Saudi Med J       Date:  2018-05       Impact factor: 1.484

Review 2.  Lipid mechanisms in hallmarks of cancer.

Authors:  J Molendijk; H Robinson; Z Djuric; M M Hill
Journal:  Mol Omics       Date:  2020-02-17

3.  The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy.

Authors:  Gui-Ming Zhang; Yao Zhu; Da-Hai Dong; Cheng-Tao Han; Cheng-Yuan Gu; Wei-Jie Gu; Xiao-Jian Qin; Li-Jiang Sun; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2015 Sep-Oct       Impact factor: 3.285

4.  Red cell distribution width is associated with presence, stage, and grade in patients with renal cell carcinoma.

Authors:  Fang-Ming Wang; Gongjun Xu; Yan Zhang; Lu-Lin Ma
Journal:  Dis Markers       Date:  2014-12-16       Impact factor: 3.434

5.  Serum lipid profiles: novel biomarkers predicting advanced prostate cancer in patients receiving radical prostatectomy.

Authors:  Gui-Ming Zhang; Xiao-Jian Qin; Hai-Liang Zhang; Wen-Jun Xiao; Yao Zhu; Cheng-Yuan Gu; Bo Dai; Guo-Hai Shi; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

Review 6.  Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential.

Authors:  Chang-Feng Deng; Neng Zhu; Tan-Jun Zhao; Hong-Fang Li; Jia Gu; Duan-Fang Liao; Li Qin
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

Review 7.  The Role of Metabolic Factors in Renal Cancers.

Authors:  Jacek Rysz; Beata Franczyk; Janusz Ławiński; Robert Olszewski; Anna Gluba-Brzózka
Journal:  Int J Mol Sci       Date:  2020-09-30       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.